INT194942

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 2006
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 1.12
Pain Relevance 0.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (CD22) plasma membrane (CD22)
Anatomy Link Frequency
B-cells 1
stem 1
CD22 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 21 82.68 Quite High
cytokine 5 6.84 Low Low
corticosteroid 20 5.00 Very Low Very Low Very Low
Antihistamine 10 5.00 Very Low Very Low Very Low
tolerance 9 5.00 Very Low Very Low Very Low
Paracetamol 7 5.00 Very Low Very Low Very Low
methotrexate 6 5.00 Very Low Very Low Very Low
Central nervous system 3 5.00 Very Low Very Low Very Low
Analgesic 3 5.00 Very Low Very Low Very Low
cINOD 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 32 99.48 Very High Very High Very High
Apoptosis 5 99.28 Very High Very High Very High
Autoimmune Disease 53 98.52 Very High Very High Very High
Death 2 89.72 High High
Disease 54 89.24 High High
Adhesions 5 87.20 High High
Rheumatoid Arthritis 21 82.68 Quite High
Hodgkin's Disease 10 70.68 Quite High
Systemic Lupus Erythematosus 89 65.08 Quite High
Syndrome 12 63.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Targeting CD22 as a strategy for treating systemic autoimmune diseases

B-cells play an important role in the diagnosis and to some extent the pathogenesis of many autoimmune diseases.

Regulation (Targeting) of CD22 in B-cells associated with autoimmune disease
1) Confidence 0.24 Published 2007 Journal Therapeutics and Clinical Risk Management Section Title Doc Link PMC2376077 Disease Relevance 0.63 Pain Relevance 0.04
Therefore, CD22 is a candidate target for therapeutic antibodies (Tedder et al 2005b; Goldenberg 2006; Steinfeld and Youinou 2006).
Regulation (target) of CD22
2) Confidence 0.24 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376077 Disease Relevance 0.33 Pain Relevance 0
Therefore, CD22 is an attractive molecular target for therapy because of its restricted expression; it is not exposed on embryonic stem or pre-B cells, nor is it normally shed from the surface of antigen-bearing cells.
Regulation (target) of CD22 in stem
3) Confidence 0.22 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526638 Disease Relevance 0.16 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox